Trade

with

Bioline Rx Ltd
(NASDAQ: BLRX)
AdChoices
=
1.36
0.00
0.00%
After Hours :
-
-
-

Open

1.35

Previous Close

1.36

Volume (Avg)

49.93k (73.73k)

Day's Range

1.33-1.40

52Wk Range

1.26-3.34

Market Cap.

46.40M

Dividend Rate ( Yield )

-

Beta

2.90

Shares Outstanding

34.12M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -16.47M

    • Market Cap.

    • 46.40M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.90

    • Forward P/E

    • 18.45

    • Price/Sales

    • -

    • Price/Book Value

    • 1.73

    • Price/Cash flow

    • -2.41

      • EBITDA

      • -14.33M

      • Return on Capital %

      • -51.63

      • Return on Equity %

      • -66.68

      • Return on Assets %

      • -51.63

      • Book Value/Share

      • 0.79

      • Shares Outstanding

      • 34.12M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 7.20

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.26

        • Cashflow Estimate

        • 0.32

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.31

              • 2.92

              • Quick Ratio

              • 12.20

              • 2.35

              • Interest Coverage

              • -10.54

              • 38.02

              • Leverage Ratio

              • 1.20

              • 2.21

              • Book Value/Share

              • 0.79

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.47

                • 243.90

                • P/E Ratio 5-Year High

                • -12.66

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.32

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.29

                • Price/Book Value

                • 1.70

                • 8.39

                • Price/Cash Flow Ratio

                • -2.41

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -66.68

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -51.63

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -60.90

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -16.45M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.41
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  171.84%

                  Mutual Fund Ownership

                  1.17%

                  Float

                  -

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • FCP OP MEDICAL BioHealthTrends

                  •  

                    165,794

                  • 0.00

                  • 0.48

                  • I.B.I Global Equity

                  •  

                    84,000

                  • 5.00

                  • 0.25

                  • APO Medical Opportunities

                  •  

                    61,850

                  • 0.00

                  • 0.18

                  • Harel Selected BioMed

                  •  

                    49,000

                  • -9.26

                  • 0.15

                  • PHARMA/wHEALTH

                  •  

                    26,056

                  • 0.00

                  • 0.08

                  • RIM Global CC Bioscience

                  •  

                    13,600

                  • 0.00

                  • 0.04

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fcmi Financial Corp Et AL

                  •  

                    34,803,965

                  • +350.01%

                  • 144.12

                  • Sabby Management LLC

                  •  

                    2,021,347

                  • +6.23%

                  • 5.92

                  • SENVEST INTERNATIONAL LLC

                  •  

                    1,591,367

                  • +2.68%

                  • 4.66

                  • Bvf Inc

                  •  

                    1,501,000

                  • +87.62%

                  • 4.40

                  • OrbiMed Israel GP Ltd

                  •  

                    1,135,000

                  • -57.44%

                  • 4.70

                  • Orbimed Advisors, LLC

                  •  

                    1,135,000

                  • 0.00%

                  • 3.33

                  • Opaleye Management Inc

                  •  

                    650,000

                  • -55.20%

                  • 1.91

                  • Sphera Funds Management Ltd.

                  •  

                    600,000

                  • 0.00%

                  • 1.76

                  • Oppenheim Asset Mgmt Services S.à r.l.

                  •  

                    191,850

                  • +58.88%

                  • 0.56

                  • Medical Strategy GmbH

                  •  

                    165,794

                  • 0.00%

                  • 0.48

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  -

                  Style

                  Small Value

                  Bioline Rx Ltd was incorporated in April 2003. It is a clinical stage biopharmaceutical development company, engaged in identifying, in-licensing and developing therapeutic candidates that have advantages over currently available the...morerapies or that address unmet medical needs. The Company's development pipeline consists of six clinical-stage therapeutic candidates: BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction, or AMI; BL-8040, a novel peptide for the treatment of acute myeloid leukemia (AML), stem cell mobilization and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a customized, proprietary, pen-like applicator containing a novel formulation of two acids, which is...more being developed in Europe as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease, or IBD; and BL-8020, an orally available treatment for the hepatitis C virus, or HCV, and other viral indications, with a unique mechanism of action involving the inhibition of virus-induced autophagy in host cells. The Company has three therapeutic candidates in the preclinical stages of development. The first therapeutic candidate, BL-1040, is a novel, resorbable polymer solution for use in the reduction or prevention of ventricular remodeling in patients who suffered an AMI. The second clinical-stage therapeutic candidate, BL-8040, is a novel, short peptide that functions as a high-affinity antagonist for CXCR4 used to develop for AML, stem cell mobilization and other hematological indications. The third clinical-stage therapeutic candidate, BL-7010, is a novel, non-absorbable, orally available, high-molecular-weight co-polymer used for the treatment of celiac disease.lessless

                  Key People

                  Dr. Kinneret Savitsky, PhD

                  CEO

                  Dr. Aharon Schwartz,PhD

                  Chairman of the Board/Director

                  Mr. Philip Serlin

                  CFO/COO

                  Mr. David Malek

                  Vice President, Divisional

                  Dr. Arnon Aharon, M.D.

                  Vice President, Divisional

                  • Bioline Rx Ltd

                  • 19 Hartum Street

                  • Jerusalem, 9777518

                  • ISR.Map

                  • Phone: +972 25489100

                  • Fax: +972 25489101

                  • biolinerx.com

                  Incorporated

                  2003

                  Employees

                  43

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: